Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent <i>Clostridioides difficile</i> Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study

Authors

Carolyn D. Alonso (ORCID: https://orcid.org/0000-0002-3140-1128)
Beth Guthmueller
Erik R. Dubberke (ORCID: https://orcid.org/0000-0003-3779-2796)
Monique R. Bidell (ORCID: https://orcid.org/0000-0003-1136-6705)
Glenn Tillotson (ORCID: https://orcid.org/0000-0002-2221-008X)
Monika Fischer (ORCID: https://orcid.org/0000-0001-7162-6172)
Frederikke Hoeyer

Institutions

Indiana University Health (US)
Beth Israel Deaconess Medical Center (US)
Harvard University (US)
Washington University in St. Louis (US)
Ferring Pharmaceuticals (United States) (US)
Ferring Pharmaceuticals (Denmark) (DK)
Indiana University – Purdue University Indianapolis (US)

Publication Details

Journal: Open Forum Infectious Diseases
Published: 2025-03-04
DOI: https://doi.org/10.1093/ofid/ofaf117
Citations: 3
Primary Topic: Clostridium difficile and Clostridium perfringens research
Type: article
Field-Weighted Citation Impact: 4.19

Funders

Ferring Pharmaceuticals

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study

Carolyn D. Alonso, Beth Guthmueller, Erik R. Dubberke, Monique R. Bidell et al.

Mar 4, 2025

3 citations

Open Forum Infectious Diseases

Clostridium difficile and Clostridium perfringens research

4.19

article

Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study

Carolyn D. Alonso, Beth Guthmueller, Erik R. Dubberke, Monique R. Bidell, Glenn Tillotson, Monika Fischer, Frederikke Hoeyer

March 4, 2025article en

3 citations

Abstract

No abstract available for this paper.

Open Forum Infectious DiseasesVol. 12(4)

Indiana University Health (US), Beth Israel Deaconess Medical Center (US), Harvard University (US), Washington University in St. Louis (US), Ferring Pharmaceuticals (United States) (US), Ferring Pharmaceuticals (Denmark) (DK), Indiana University – Purdue University Indianapolis (US)

Ferring Pharmaceuticals

Good health and well-being

Openalex Percentile: Top 7%

Clostridium difficile and Clostridium perfringens research

4.19

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent <i>Clostridioides difficile</i> Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study — Carolyn D. Alonso, Beth Guthmueller, et al. · Open Forum Infectious Diseases (2025) | TGRS Research Map | TGRS